Neurogene (NGNE) Common Equity (2013 - 2026)
Neurogene (NGNE) recorded Common Equity of $217.13 million in Q2 2026, down 20.5% from $273.26 million a year earlier and down 8.7% from the prior quarter.
Neurogene (NGNE) Common Equity (2013 - 2026) Analysis & Trends
At the end of FY2025, Neurogene reported Common Equity of $264.89 million, down 14.7% from FY2024.
- Annual Common Equity has a five-year compound annual growth rate of 6.7% (FY2020 to FY2025).
- Across earlier years, Common Equity came in at $310.38 million in FY2024 (+66.8%), $186.02 million in FY2023, -$145.74 million in FY2022 and -$91.88 million in FY2021.
- The Q2 2026 figure is the lowest quarterly Common Equity since Q3 2024.
- On a year-over-year basis, Common Equity has declined for three consecutive quarters, with growth averaging 36.2% over the last seven quarters.
- Peak year-over-year performance for Common Equity in the last five years was growth of 93.2% in Q3 2025, against a decline of 31.8% in Q3 2022 at the low end.
- Per Business Quant, the preceding three quarters came in at $237.78 million (Q1 2026), $264.89 million (Q4 2025) and $265.54 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 41.98 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 50.37 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 11.69 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 11.83 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 85.49 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 20.25 Bn |
| 10 | Neurogene | 642.28 Mn | 642.28 Mn | - | 217.13 Mn |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 217.13 Mn |
| Mar 31, 2026 | 237.78 Mn |
| Dec 31, 2025 | 264.89 Mn |
| Sep 30, 2025 | 265.54 Mn |
| Jun 30, 2025 | 273.26 Mn |
| Mar 31, 2025 | 291.80 Mn |
| Dec 31, 2024 | 310.38 Mn |
| Sep 30, 2024 | 137.41 Mn |
| Jun 30, 2024 | 155.01 Mn |
| Mar 31, 2024 | 170.78 Mn |
| Dec 31, 2023 | 186.02 Mn |
| Sep 30, 2023 | -183.21 Mn |
| Jun 30, 2023 | -169.05 Mn |
| Mar 31, 2023 | -157.60 Mn |
| Dec 31, 2022 | -145.74 Mn |
| Sep 30, 2022 | 105.65 Mn |
| Jun 30, 2022 | 116.71 Mn |
| Mar 31, 2022 | 130.09 Mn |
| Dec 31, 2021 | -91.88 Mn |
| Sep 30, 2021 | 154.87 Mn |
Neurogene Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=NGNE&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "NGNE", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=NGNE&period=max&api_key=YOUR_API_KEY");
const data = await res.json();